PSORIASIS: CORRELATION BETWEEN SEVERITY INDEX AND QUALITY OF LIFE INDEX (DLQI) IN PATIENTS ASSESSED BEFORE AND AFTER TREATMENT WITH ACITRETIN
Main Article Content
Keywords
Acitretin, DLQI, PASI, Psoriasis, Quality of Life
Abstract
Background: Psoriasis is a chronic inflammatory skin disease affecting approximately 125 million individuals globally. It significantly impairs physical and emotional well-being, with diverse treatment modalities aimed at managing its symptoms. Acitretin, an oral retinoid, is recognized for its efficacy in moderating disease severity and enhancing life quality, measured through the Psoriasis Area Severity Index (PASI) and Dermatology Life Quality Index (DLQI).
Objective: This study aims to evaluate the effectiveness of Acitretin in reducing PASI scores and improving DLQI scores among psoriasis patients.
Methods: Conducted at PIMS hospital, Islamabad, this analytical study enrolled 43 patients with plaque psoriasis over six months. Participants, aged between 11 and 60 years, were administered 0.5 mg/kg/day of Acitretin and monitored for PASI and DLQI scores pre- and post-treatment after 3 months. Statistical analysis was performed using paired t-tests via SPSS version 23.
Results: Significant improvements were noted post-treatment, with a mean reduction in PASI scores from initial values down by 6.60 (SD=2.41) and DLQI scores by 7.16 (SD=2.68). Both changes were statistically significant (p < 0.001), demonstrating substantial clinical and quality of life enhancements.
Conclusion: The study confirms that Acitretin effectively reduces the severity of plaque psoriasis and improves patients' quality of life, reinforcing the importance of continuous monitoring and patient-centered care in treatment plans.
References
2. Zhong X-Y, Li Y, Ma R, Wang X, Yu Y-Y, Yu N, et al. Impact of Adverse Events Associated With Acitretin Treatment of Moderate-to-Severe Plaque Psoriasis: Based on an Observational, Single-Center Study in Shanghai, China. International Journal of Dermatology and Venereology. 2023;6(02):61-6.
3. Naldi L, Svensson A, Diepgen T, Elsner P, Grob J-J, Coenraads P-J, et al. Randomized clinical trials for psoriasis 1977–2000: the EDEN survey. Journal of investigative dermatology. 2003;120(5):738-41.
4. Robinson S, Moon TM, Eng TK, Yuen TT, Jong TJ, Selvarajah L, et al. Dermatology Life Quality Index in Patients with Psoriasis Treated with Biologic Versus Non-biologic Treatment in Malaysia: A Retrospective Cross-Sectional Study. Drugs-real world outcomes. 2023;10(2):291-8.
5. Patel PM, Sanchez‐Melendez SN, Nambudiri VE. A narrative review of studies assessing the quality of life in patients with generalized pustular psoriasis. Experimental Dermatology. 2023;32(8):1227-34.
6. Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. Jama. 2003;290(23):3073-80.
7. Ecer N, Ecer M, Uçmak D. Clinical examination and demographic characteristics of 277 patients with psoriasis. TURKDERM-Turkish Archives of Dermatology and Venereology. 2023;57(1):16-23.
8. Alabas OA, Mason KJ, Yiu ZZ, Hampton PJ, Reynolds NJ, Owen CM, et al. Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for patients with moderate-to-severe psoriasis: a cohort study from BADBIR. British Journal of Dermatology. 2023;188(5):618-27.
9. Seng TK, Nee TS. Group therapy: a useful and supportive treatment for psoriasis patients. International Journal of Dermatology. 1997;36(2):110-2.
10. Bu J, Ding R, Zhou L, Chen X, Shen E. Epidemiology of psoriasis and comorbid diseases: a narrative review. Frontiers in immunology. 2022;13:880201.
11. Putra PB, Rahmawati KN, Yulinvia AT, Radiono S, Oktarina DAM. Clinical and Life Quality Improvement, and IL-17 Serum Level in Psoriasis Patients Treated with Metothrexate Injection: A Pilot Study in 15 Severe Psoriasis Cases. 2021.
12. AY F. Validation of sickness impact profile and psoriasis disability index in psoriasis. Br J Dermatol. 1990;123:751-6.
13. Kumsa SM, Tadesse TA, Woldu MA. Management practice, quality of life and associated factors in psoriasis patients attending a dermatological center in Ethiopia. Plos one. 2021;16(11):e0260243.
14. Bonifati C, Capoccia R, Graceffa D, Morrone A. Effectiveness of systemic therapies in patients with obesity and psoriasis: a single-center retrospective study. Acta Dermatovenerologica Croatica. 2021;29(2):88-93.
15. Augustin M, Dauden E, Mrowietz U, Konstantinou M, Gerdes S, Kingo K, et al. Secukinumab treatment leads to normalization of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: the PROSE study results. Journal of the European Academy of Dermatology and Venereology. 2021;35(2):431-40.
16. Armstrong AW, Mehta MD, Schupp CW, Gondo GC, Bell SJ, Griffiths CE. Psoriasis prevalence in adults in the United States. JAMA dermatology. 2021;157(8):940-6.
17. Van de Kerkhof P, Loewe R, Mrowietz U, Falques M, Pau‐Charles I, Szepietowski J. Quality of life outcomes in adults with moderate‐to‐severe plaque psoriasis treated with dimethylfumarate (DMF): a post hoc analysis of the BRIDGE study. Journal of the European Academy of Dermatology and Venereology. 2020;34(1):119-26.
18. Mendonça J, Machado E, Arruda A, Pansani L, Mimoto M, Brandão L. EXISTEM OUTROS PARÂMETROS DO DOPPLER ESPECTRAL QUE PODEM MOSTRAR ENTESITE UNGUEAL NA PSORÍASE? Revista Brasileira de Reumatologia. 2017;57:S134-S5.
19. Silva MFPd, Fortes MRP, Miot LDB, Marques SA. Psoriasis: correlation between severity index (PASI) and systemic treatment. Anais brasileiros de dermatologia. 2013;88(5):760-3.
20. Lebwohl M, Papp K, Han C, Schenkel B, Yeilding N, Wang Y, et al. Ustekinumab improves health‐related quality of life in patients with moderate‐to‐severe psoriasis: results from the PHOENIX 1 trial. British Journal of Dermatology. 2010;162(1):137-46.
21. Bronsard V, Paul C, Prey S, Puzenat E, Gourraud PA, Aractingi S, et al. What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature. Journal of the European Academy of Dermatology and Venereology. 2010;24:17-22.
22. Reich K, Griffiths CE. The relationship between quality of life and skin clearance in moderate-to-severe psoriasis: lessons learnt from clinical trials with infliximab. Archives of dermatological research. 2008;300:537-44.
23. Menter A, Gordon K, Carey W, Hamilton T, Glazer S, Caro I, et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Archives of dermatology. 2005;141(1):31-8.
24. Griffiths C, Smith CH, Anstey A, Barker JN, Burden A, Chalmers RJ, et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. British Journal of Dermatology. 2005;153(3):486-97.
25. Martins GA, Arruda L, Mugnaini ASB. Validation of life quality questionnaires for psoriasis patients. Anais Brasileiros de Dermatologia. 2004;79:521-35.
26. Martins GA, Arruda L. Systemic treatment of psoriasis-Part I: methotrexate and acitretin. Anais Brasileiros de Dermatologia. 2004;79:263-78.
27. Prevezas C, Katoulis AC, Papadavid E, Panagakis P, Rigopoulos D. Short-term correlation of the Psoriasis Area Severity Index, the Nail Psoriasis Area Severity Index, and the Dermatology Life Quality Index, before and after treatment, in patients with skin and nail psoriasis. Skin Appendage Disorders. 2019;5(6):344-9.
28. Houghton K, Patil D, Gomez B, Feldman SR. Correlation between change in psoriasis area and severity index and dermatology life quality index in patients with psoriasis: pooled analysis from four phase 3 clinical trials of secukinumab. Dermatology and Therapy. 2021;11(4):1373-84.
29. Al-Oudah GA, Sahib AS, Al-Hattab MK, Al-Ameedee AA. Effect of CoQ10 Administration to Psoriatic Iraqi Patients on Biological Therapy Upon Severity Index (PASI) and Quality of Life Index (DLQI) Before and After Therapy. Journal of Population Therapeutics and Clinical Pharmacology= Journal de la Therapeutique des Populations et de la Pharmacologie Clinique. 2022;29(2):e52-e60.
30. Loft ND, Egeberg A, Rasmussen MK, Bryld LE, Gniadecki R, Dam TN, et al. Patient-reported outcomes during treatment in patients with moderate-to-severe psoriasis: a Danish nationwide study. Acta Dermato-Venereologica. 2019;99(13):1224-30.
31. Gerdes S, Körber A, Biermann M, Karnthaler C, Reinhardt M. Absolute and relative psoriasis area and severity index (PASI) treatment goals and their association with health-related quality of life. Journal of Dermatological Treatment. 2020;31(5):470-5.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr. Huma Imran
FCPS (Resident of Dermatology), PIMS, Islamabad Pakistan
Dr. Riaz Khan Marwat
Head of Department (Department of Dermatology), PIMS, Islamabad Pakistan
Dr. Umer Imran Dhillon
MBBS (4th Year Student), Foundation University Medical College (FUMC), Islamabad Pakistan
Dr. Ali Imran Dhillon
FCPS (Resident Pediatrics), PAEC General Hospital, Islamabad Pakistan
Dr. Amina Imran
BDS, AMC, Rawalpindi Pakistan
Dr. Javeria Hasan
FCPS (Resident General Medicine), PIMS, Islamabad Pakistan
Dr. Sulman Bajwa
Consultant Pediatric Surgeon, PAF Hospital, Islamabad Pakistan